# Phase 1 Burkitt Lymphoma trials recruiting: 41 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 41 trials in phase 1 for Burkitt Lymphoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Burkitt Lymphoma trials: 41 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/burkitt-lymphoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 41
- Recruiting or not yet: 41
- Read on: November 19, 2026

## Trials

The 25 newest of 41, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 13, 2026 | NCT07936266 | Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R... | Sponsor not shown (see the record) | Phase 1 | Recruiting | B-cell Acute Lymphoblastic Leukemia (B-ALL) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936266) |
| November 10, 2026 | NCT07927816 | CD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | Sponsor not shown (see the record) | Phase 1 | Recruiting | Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia, In Vivo CAR-T, B-Cell Acute Lymphoblastic Leukemia | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07927816) |
| November 2, 2026 | NCT07910708 | GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia | Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital | Phase 1 | Recruiting | Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910708) |
| October 26, 2026 | NCT07896213 | Metabolically Fit CD19 CAR T Cells With CD34 Selection Markers in Adults With CD19-Positive B-Cell Acute Lymphocytic Leukemia | Medical University of South Carolina | Phase 1 | Not yet recruiting | CD19 Positive, B-ALL, B-cell Acute Lymphocytic Leukemia, Chimeric Antigen Receptor T-cell, CAR-T Cell Therapy, MRD... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896213) |
| October 20, 2026 | NCT07883941 | Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid... | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies, Diffuse Large B Cell Lymphoma... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883941) |
| October 9, 2026 | NCT07869368 | BLinatumomab and iNKT in Relapsed B-Cell ALL | UNC Lineberger Comprehensive Cancer Center | Phase 1 | Not yet recruiting | B-Cell ALL, ALL (Acute B-Lymphoblastic Leukemia), Philadelphia Chromosome-Negative Lymphoblastic Leukemia... | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869368) |
| September 24, 2026 | NCT07838714 | Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic... | Ruijin Hospital | Phase 1 | Recruiting | B-cell Acute Lymphoblastic Leukemia | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07838714) |
| August 11, 2026 | NCT07758673 | Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell... | City of Hope Medical Center | Phase 1 | Recruiting | Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic... | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07758673) |
| June 30, 2026 | NCT07674823 | Study Of KITE-753 in R/R B-Cell ALL | M.D. Anderson Cancer Center | Phase 1 | Not yet recruiting | B-cell Acute Lymphoblastic Leukemia | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07674823) |
| April 20, 2026 | NCT07539610 | Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly... | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | Not yet recruiting | B-Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia/Lymphoma | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07539610) |
| April 16, 2026 | NCT07532525 | Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma | University of Michigan Rogel Cancer Center | Phase 1 | Recruiting | Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07532525) |
| November 20, 2025 | NCT07239323 | In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma, Multiple Myeloma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07239323) |
| November 18, 2025 | NCT07234045 | A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | Not yet recruiting | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Relapsed/Refractory B-cell ALL | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07234045) |
| August 21, 2025 | NCT07133997 | Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive... | City of Hope Medical Center | Phase 1 | Recruiting | Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07133997) |
| August 8, 2025 | NCT07113496 | RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies | The First Affiliated Hospital with Nanjing Medical University | Phase 1 | Not yet recruiting | Relapsed or Refractory B-cell Hematologic Malignancies, B-cell Acute Lymphoblastic Leukemia (B-ALL), Multiple Myeloma... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07113496) |
| August 6, 2025 | NCT07106749 | CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | Recruiting | Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia/Lymphoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07106749) |
| July 22, 2025 | NCT07078929 | Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL) | Chulalongkorn University | Phase 1 | Recruiting | Relapse B Acute Lymphoblastic Leukemia, Refactory Childhood Acute Lymphoblastic Leukemia | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07078929) |
| June 29, 2025 | NCT07043218 | A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | Shanghai Tongji Hospital, Tongji University School of Medicine | Phase 1 | Not yet recruiting | B-cell Acute Lymphoblastic Leukemia | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07043218) |
| April 15, 2025 | NCT06927466 | A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory... | Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. | Phase 1 | Recruiting | Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06927466) |
| March 17, 2025 | NCT06879340 | Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies | University of Kansas Medical Center | Phase 1 | Recruiting | B-Cell Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06879340) |
| March 7, 2025 | NCT06863259 | Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL | Children's Hospital Medical Center, Cincinnati | Phase 1 | Recruiting | B-cell Acute Lymphoblastic Leukemia | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06863259) |
| January 16, 2025 | NCT06777979 | CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia | St. Jude Children's Research Hospital | Phase 1 | Recruiting | Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06777979) |
| August 19, 2024 | NCT06559189 | CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL | University of Colorado, Denver | Phase 1 | Recruiting | B-cell Acute Lymphoblastic Leukemia | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06559189) |
| July 18, 2024 | NCT06507514 | Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL | The First Affiliated Hospital of Soochow University | Phase 1 | Recruiting | B-cell Acute Lymphoblastic Leukemia | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06507514) |
| April 1, 2024 | NCT06340737 | AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas | Stanford University | Phase 1 | Recruiting | Follicular Lymphoma, Mantle Cell Lymphoma, Hairy Cell Leukemia, Lymphoplasmacytic Lymphoma, Burkitt Lymphoma, Marginal... | 148 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06340737) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Institute of Hematology & Blood Diseases Hospital, China | 3 |
| City of Hope Medical Center | 2 |
| Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. | 1 |
| Medical College of Wisconsin | 1 |
| Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital | 1 |
| National Cancer Institute (NCI) | 1 |
| Fifth Affiliated Hospital, Sun Yat-Sen University | 1 |
| Children's Hospital Medical Center, Cincinnati | 1 |
| Autolus Limited | 1 |
| [Ascentage Pharma Group Inc.](https://specstream.ai/data/clinical-trials/company/ascentage-pharma-group-inc) | 1 |
| Peking University Third Hospital | 1 |
| Vincerx Pharma, Inc. | 1 |
| University of Colorado, Denver | 1 |
| UNC Lineberger Comprehensive Cancer Center | 1 |
| Ruijin Hospital | 1 |
| St. Jude Children's Research Hospital | 1 |
| British Columbia Cancer Agency | 1 |
| Shanghai Tongji Hospital, Tongji University School of Medicine | 1 |
| University of Kansas Medical Center | 1 |
| M.D. Anderson Cancer Center | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
| Medical University of South Carolina | 1 |
| University of Michigan Rogel Cancer Center | 1 |
| The First Affiliated Hospital of Soochow University | 1 |
| Imugene Limited | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 22 |
| China | 13 |
| Spain | 2 |
| Canada | 2 |
| Italy | 2 |
| United Kingdom | 1 |
| Australia | 1 |
| France | 1 |
| Moldova | 1 |
| Poland | 1 |
| Romania | 1 |
| Ukraine | 1 |
| Thailand | 1 |
| Czechia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Backflow companies in the United States](https://specstream.ai/data/businesses/backflow-companies/united-states)
- [Pediatric surgery practices in the United States](https://specstream.ai/data/businesses/pediatric-surgery-practices/united-states)
- [Drama schools in the United States](https://specstream.ai/data/businesses/drama-schools/united-states)
- [Tea wholesalers in the United States](https://specstream.ai/data/businesses/tea-wholesalers/united-states)
- [Hydraulic equipment suppliers in the United States](https://specstream.ai/data/businesses/hydraulic-equipment-suppliers/united-states)
- [B2B industrial and machine companies in the United States](https://specstream.ai/data/businesses/b2b-industrial-and-machine-companies/united-states)
